- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Reckitt Benckiser LLC v. Amneal Pharms. LLC
In view of its claim construction and expert credibility findings, the Court found generic manufacturers’ proposed products did not infringe the patents-in-suit.
October 20, 2017
Case Name: Reckitt Benckiser LLC v. Amneal Pharms. LLC, Nos. 15-2155 (RMB/JS), 15-4524 (RMB/JS), 2017 U.S. Dist. LEXIS 133998 (D.N.J. Aug. 22 2017) (Bumb, J.)
Drug Product and Patent(s)-in-Suit: Mucinex® (guaifenesin); U.S. Patents Nos. 6,955,821 (“the ’821 patent”) and 7,838,032 (“the ’032 patent”)
Nature of the Case and Issue(s) Presented: Reckitt Benckiser’s (“RB”) Mucinex product is an expectorant that thins and loosens mucus and relieves chest congestion. At issue was whether Amneal’s generic guaifenesin sustained-release tablets (“Amneal’s ANDA products”) and Dr. Reddy’s (“DRL”) generic guaifenesin and pseudoephedrine hydrochloride sustained-release tablets (“DRL’s ANDA Products”) infringed the patents-in-suit.
More specifically, Amneal stipulated that its ANDA products satisfy every limitation of the asserted claims of the ’821 patent except for the elements: “modified release drug product;” “first quantity of guaifenesin in an immediate release formulation;” and “second quantity of guaifenesin in a sustained release form/release-delaying matrix.”
With respect to the ’032 patent, DRL and Amneal stipulated that their respective ANDA products satisfy every limitation of the relevant claims except for the following claim elements directed to the drug product having two portions of guaifenesin: “a first portion comprises guaifenesin in an immediate release form;” and “a second portion comprises guaifenesin in a sustained release form.”
Defendants’ invalidity claims were stayed pending the outcome of the infringement trial. The court found that neither Amneal’s ANDA products nor DRL’s ANDA Products infringed the patents-in-suit.
Why Defendants Prevailed: The court construed the claims to require the presence of two distinct formulations. Illustratively, for the ’032 patent, the court construed “portion” to mean “a distinct formulation,” in accord with the construction in Reckitt v. Aurobindo Pharma Ltd. 2016 U.S. Dist. LEXIS 152337 (D. Del. Nov. 3, 2016). This construction, and a similar one for the ’821 patent, proved dispositive. The court found all asserted claims non-infringed.
RB’s expert attempted, by performing Raman spectroscopy on thin layers cut from the products with a microtome, to demonstrate that each of the accused products had two formulations. The defendants offered a litany of criticisms to the expert’s opinions, and the court generally agreed. One criticism was the expert’s inability to identify half of the ingredients in one tablet. Another one, and the “most troubling” one, in the court’s opinion, was that using the expert’s methodology, “an SR formulation could be transformed into an IR formulation simply by cutting off the original surface of the tablets. No matter how many times the tablet was cut, the outer layer would transform into the IR formulation even though it had been the SR formulation.”
The court summarized its view of RB’s expert opinion by stating:
In the end, the Court finds that Defendants’ criticisms of [the expert’s] Raman analyses were well-placed and called into question the reliability of [his] opinion. However, as alluded to above, [his] interpretations [of] the maps created by those analyses present a greater issue. [His] testimony leads this Court to the conclusion that, with some creative thinking, one could define any region of a tablet as having a distinct formulation.
The court buttressed its conclusion that the accused products did not infringe by reviewing the evidence of defendants’ efforts to create a tablet having only a single formulation. Reckitt, the court found, failed to identify any step in the process that could result in the creation of two distinct formulations.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.